Decision Trail
Stage 1: Scope Fit
Feb 7, 2026, 05:22 PMGoRisk: 0%
| Rule | Input | Result | Explanation |
|---|---|---|---|
| modality IN_LIST biologics, gene_therapy, gene therapy, cell_therapy, cell therapy, adc, antibody drug conjugate | peptide | PASS | modality passed check |
| scale IN_LIST commercial_dp, commercial drug product, commercial scale | 500 grams | PASS | scale passed check |
| modality CONTAINS hpapi category 4 | peptide | PASS | modality passed check |
| timeline CONTAINS urgent, asap, rush, immediate | IND filing by end of next year | PASS | timeline passed check |
| devStage IN_LIST phase 1, phase 2, phase 3, clinical, preclinical | Preclinical | GO | Clinical-stage work is core CDMO capability |
| modality IN_LIST small molecule, peptide, oligonucleotide | peptide | GO | Modality within standard CDMO capabilities |
Already answered by narrative:
- modality already answered: "peptide" (confidence: 0.95)
- scale already answered: "500 grams" (confidence: 0.90)
- modality already answered: "peptide" (confidence: 0.95)
- timeline already answered: "IND filing by end of next year" (confidence: 0.85)
- devStage already answered: "Preclinical" (confidence: 0.90)
- modality already answered: "peptide" (confidence: 0.95)
Stage 2: Feasibility
Feb 7, 2026, 05:22 PMGoRisk: 22%
| Rule | Input | Result | Explanation |
|---|---|---|---|
| Technical Complexity SCORE > 0.5 | 0.60 | GO | May require specialized process development |
| Scale Feasibility SCORE > 0.5 | 0.90 | GO | Scale within standard capacity |
| GMP Implications SCORE > 0.5 | 0.70 | GO | GMP manufacturing required - standard GMP protocols apply |
| Analytical Burden SCORE > 0.5 | 0.80 | GO | Analytical requirements manageable |
| Timeline Realism SCORE > 0.5 | 0.80 | GO | Timeline appears reasonable |
| Safety Risks SCORE > 0.5 | 0.90 | GO | No significant safety concerns identified |